Discontinuation of statin therapy in older people: Does a cancer diagnosis make a difference? An observational cohort study using data linkage

BMJ Open

Volumn 2, Issue 3, 2012, Pages

  Stavrou, Efty P ^a   Buckley, Nicholas ^a   Olivier, Jake ^a   Pearson, Sallie Anne ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ARTICLE; AUSTRALIA; BRONCHUS CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISTANT METASTASIS; DRUG FATALITY; DRUG WITHDRAWAL; FOLLOW UP; GOVERNMENT; HUMAN; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; TRACHEA CANCER; UPPER GASTROINTESTINAL TRACT;

EID: 84863709102     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-000880     Document Type: Article

References (27)

1. Hall P, Lord S, El-Laboudi A, et al. Non-cancer medications for patients with incurable cancer: time to stop and think. Br J Gen Pract 2010;60:243-4.
2. Tanvetyanon T, Choudhury A. Physician practice in the discontinuation of statins among patients with advanced lung cancer. J Palliat Care 2006;22:281-5.
3. Stevenson JP, Currow D, Abernathy A, et al. The broader implications of managing statins at the end of life. J Palliat Care 2007;23:188-9.
4. Riechelmann R, Krzyzanowska MK, Zimmermann C. Futile medication use in terminally ill cancer patients. SupportCareCancer 2009;17:745-8.
5. Fede A, Miranda M, Antonangelo D, et al. Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer 2011;19:1313-18.
6. Silveira M, Segnini Kazanis A, Shevrin M. Statins in the last six months of life: a recognizable, life-limiting condition does not decrease their use. J Palliat Med 2008;11:685-93. (Pubitemid 351918845)
7. Vollrath A, Sinclair C, Hallenbeck J. Discontinuing cardiovascular medications at the end of life: lipid-lowering agents. J Palliat Med 2005;8:876-81. (Pubitemid 41266265)
8. Abernathy A, Aziz N, Basch E, et al. A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group. J Palliat Med 2010;13:1407-13.
9. Davis G. Discontinuing lipid-lowering agents. J Palliat Med 2006;9:619-21.
10. Amarenco P, Labreuche J, Lavallee P, et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2002;35:2902-9.
11. Sever P, Dahlof B, Poulter N, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58. (Pubitemid 36398384)
12. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30. (Pubitemid 35379733)
13. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atheroscelrosis Prevention Study. JAMA 1998;279:1615-22. (Pubitemid 28248586)
14. Ballantyne C, Corsini A, Davidson M, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553-64. (Pubitemid 36314342)
15. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-28.
16. Newman C, Palmer G, Silbershatz H, et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 2003;92:670-6. (Pubitemid 37103016)
17. Department of Veterans' Affairs (DVA). Annual Report 2006-2007. Canberra: DVA, 2007.
18. Department of Veterans' Affairs Rehabilitation RaDG. Treatment Population Statistics. Quarterly Report September 2007. Canberra: Department of Veretans' Affairs, 2007.
19. Rossi S, ed. The Australian Medicines Handbook (AMH). 12th edn. Adelaide: Australian Medicines Handbook Pty Ltd 2011.
20. Percy C, Van Holten V, Muir C, eds. ICD-O International Classifi Cation of Diseases for Oncology. 3rd edn. Geneva: WHO, 1990.
21. AIHW (Australian Institute of Health and Welfare) & AACR (Australasian Association of Cancer Registries). Cancer in Australia: An Overview, 2008. Cancer Series No. 46. Cat No. CAN 42. Canberra: AIHW, 2008.
22. Tracey E, Kerr T, Dobrovic A, et al. Cancer in NSW: Incidence and Mortality Report 2008. Sydney: Cancer Institute NSW, 2010.
23. Latry P, Molimard M, Dedieu B, et al. Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study. BMC Cardiovasc Disord 2011;11:46. http://www. biomedcentral.com/1471-2261/11/46
24. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index: C10AA HMG CoA Reductase Inhibitors. Oslo: World Health Organization, 2011.
25. Lu CY, Barratt J, Vitry A, et al. Charlson and Rx-risk comorbidity indices were predictive of mortality in the Australian health care setting. J Clin Epidemiol 2011;64:223-8.
26. Vitry A, Wong SA, Roughead EE, et al. Validity of medication-based co-morbidity indicies in the Australian elderly population. Aust N Z J Public Health 2009;33:126-30.
27. Maggiore RJ, Gross CP, Hurria A. Polypharmacy in older adults with cancer. Oncologist 2010;15:507-22.